| scholarly article | Q13442814 |
| P50 | author | Jeong Han Kim | Q37837632 |
| Kyun-Hwan Kim | Q38324563 | ||
| P2093 | author name string | Eun-Sook Park | |
| Yong Kwang Park | |||
| P2860 | cites work | A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients | Q46757241 |
| Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. | Q46913808 | ||
| Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. | Q54599747 | ||
| Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study | Q58097173 | ||
| Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome | Q58235835 | ||
| Mutation rate of the hepadnavirus genome | Q58396490 | ||
| Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B | Q82240888 | ||
| Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B | Q83395636 | ||
| Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants | Q83494028 | ||
| Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance | Q84408660 | ||
| Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy | Q84446263 | ||
| Telbivudine versus lamivudine in patients with chronic hepatitis B | Q28261708 | ||
| Antiviral L-nucleosides specific for hepatitis B virus infection | Q28345251 | ||
| EASL clinical practice guidelines: Management of chronic hepatitis B virus infection | Q29615868 | ||
| Chronic hepatitis B: update 2009 | Q29617409 | ||
| Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments | Q30830513 | ||
| Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization | Q30853725 | ||
| Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil | Q33233245 | ||
| Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough | Q33240085 | ||
| Comparison of mass spectrometric analysis and TRUGENE HBV genotyping for monitoring lamivudine resistance in chronic hepatitis B patients. | Q33284655 | ||
| Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy | Q33417353 | ||
| Discovery and Development of Anti-HBV Agents and Their Resistance | Q33677072 | ||
| Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. | Q33826784 | ||
| Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures | Q34302587 | ||
| Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. | Q34500537 | ||
| Lamivudine for patients with chronic hepatitis B and advanced liver disease | Q34551713 | ||
| Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay | Q34569230 | ||
| 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. | Q34600796 | ||
| Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update | Q35706189 | ||
| A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients | Q35845689 | ||
| High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B. | Q35890599 | ||
| Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. | Q35964704 | ||
| Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir | Q36018658 | ||
| KASL Clinical Practice Guidelines: Management of chronic hepatitis B. | Q36153966 | ||
| Long-term treatment efficacy and safety of clevudine therapy in naïve patients with chronic hepatitis B. | Q36385195 | ||
| HBV drug resistance: mechanisms, detection and interpretation | Q36385242 | ||
| Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B. | Q36492636 | ||
| Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B. | Q36756364 | ||
| Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. | Q36780274 | ||
| Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management | Q36863124 | ||
| Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients. | Q36969950 | ||
| Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen | Q37099761 | ||
| Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients | Q37229870 | ||
| Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV) | Q37278141 | ||
| Antiviral drug resistance increases hepatocellular carcinoma: a prospective decompensated cirrhosis cohort study | Q37378970 | ||
| Management and prevention of drug resistance in chronic hepatitis B. | Q37389945 | ||
| Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections | Q37465040 | ||
| Oligonucleotide chip for detection of Lamivudine-resistant hepatitis B virus | Q37511150 | ||
| Hepatitis B virus resistance to nucleos(t)ide analogues. | Q37593697 | ||
| Treatment of chronic hepatitis B: Evolution over two decades. | Q37825658 | ||
| Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity | Q37978441 | ||
| Management of treatment failure in chronic hepatitis B. | Q37980893 | ||
| Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. | Q38475543 | ||
| Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy | Q39455322 | ||
| The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains | Q39876916 | ||
| Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir | Q39913000 | ||
| In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents | Q40115548 | ||
| A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. | Q40513014 | ||
| In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector | Q40543425 | ||
| A comparison of clevudine and entecavir for treatment-naïve patients with chronic hepatitis B: results after 2 years of treatment | Q40707675 | ||
| Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection | Q41604155 | ||
| Mutations in HBV DNA polymerase associated with nucleos(t)ide resistance are rare in treatment-naive patients | Q42248759 | ||
| Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil | Q42271419 | ||
| No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. | Q42277100 | ||
| Efficacy and safety of pegylated interferon-α2a in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B. | Q42280370 | ||
| A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. | Q42541246 | ||
| Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. | Q42678962 | ||
| No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus | Q42693130 | ||
| Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B. | Q42780959 | ||
| Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. | Q42876001 | ||
| Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. | Q42989166 | ||
| Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. | Q43102284 | ||
| Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues | Q43149262 | ||
| Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. | Q43187480 | ||
| Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. | Q43202400 | ||
| Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues | Q43226767 | ||
| Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir | Q43240922 | ||
| Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years | Q43914060 | ||
| Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure | Q44007169 | ||
| Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. | Q44329201 | ||
| Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. | Q44355905 | ||
| Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance. | Q44646709 | ||
| The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir. | Q44670160 | ||
| Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. | Q44671796 | ||
| Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing. | Q44675493 | ||
| Long-term safety of lamivudine treatment in patients with chronic hepatitis B. | Q44729211 | ||
| Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations | Q44837960 | ||
| Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States | Q44949690 | ||
| A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China | Q44961875 | ||
| Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. | Q45023133 | ||
| Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen. | Q45353143 | ||
| Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy | Q45354171 | ||
| Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing | Q45356427 | ||
| Hepatitis B virus variant with the a194t substitution within reverse transcriptase before and under adefovir and tenofovir therapy | Q45359579 | ||
| Successful treatment of an entecavir-resistant hepatitis B virus variant | Q45399709 | ||
| Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient | Q45408115 | ||
| Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. | Q45411398 | ||
| Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy | Q45414035 | ||
| Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. | Q45423363 | ||
| Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy | Q45748176 | ||
| Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. | Q45917918 | ||
| Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection. | Q46044243 | ||
| Chronic hepatitis B--new goals, new treatment. | Q46217480 | ||
| Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. | Q46217486 | ||
| Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up | Q46629124 | ||
| Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation | Q46707913 | ||
| Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine | Q46749895 | ||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Hepatitis B virus | Q6844 |
| hepatitis B | Q6853 | ||
| P304 | page(s) | 5708-5720 | |
| P577 | publication date | 2014-05-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Molecular diagnosis and treatment of drug-resistant hepatitis B virus | |
| P478 | volume | 20 |
| Q90040182 | A Global View to HBV Chronic Infection: Evolving Strategies for Diagnosis, Treatment and Prevention in Immunocompetent Individuals |
| Q28595162 | Clinical and biological insights from viral genome sequencing |
| Q47260781 | Direct Detection of Drug-Resistant Hepatitis B Virus in Serum Using a Dendron-Modified Microarray |
| Q40355667 | Implementation of Next-Generation Sequencing for Hepatitis B Virus Resistance Testing and Genotyping in a Clinical Microbiology Laboratory |
| Q26772346 | Overview of hepatitis B virus mutations and their implications in the management of infection |
| Q98466322 | Plasma Level of ADAMTS13 or IL-12 as an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing m-ETV Treatment |
| Q41527993 | Spontaneous reactivation of hepatitis B virus (HBV) infection in patients with resolved or occult HBV infection |
| Q28547647 | Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance |
| Q42144275 | Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance |
| Q37097615 | The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy |
| Q50190669 | Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance |
| Q26777048 | Update on hepatitis B and C virus diagnosis |
Search more.